{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000154","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.788373+00:00","generated_at":"2026-06-08T19:23:25.898422+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial","bullets":["Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.","Functional MRI showed increased brain activity in visual cortex; mobility test improvement from 24.7% to 60.0% at day 28.","No serious adverse events or retinal inflammation; duration of effect supports monthly IVT injection.","Company plans sham-controlled Phase II trial in 2024; will share ABACUS results with FDA in Q4 2023.","Patients with no light perception regained ability to perceive light; Odds Ratio 2.1-4.2 for light perception improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000154","json":"https://secwatch.observer/filing/0001372514-23-000154.json","markdown":"https://secwatch.observer/filing/0001372514-23-000154.md","text":"https://secwatch.observer/filing/0001372514-23-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/0001372514-23-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/kprx-20231104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:23:25.898422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}